Biomarin Pharmaceutical Inc (BMRN)

81.90
-1.08(-1.30%)
After Hours
81.80
-0.10(-0.12%)
- Real-time Data
  • Volume:
    1,340,479
  • Bid/Ask:
    78.00/81.85
  • Day's Range:
    81.52 - 82.90

BMRN Overview

Prev. Close
82.98
Day's Range
81.52-82.9
Revenue
1.84B
Open
82.54
52 wk Range
71.35-131.95
EPS
-0.37
Volume
1,340,479
Market Cap
14.97B
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
879,353
P/E Ratio
-
Beta
0.57
1-Year Change
-25.46%
Shares Outstanding
182,742,573
Next Earnings Date
Aug 05, 2021
What is your sentiment on Biomarin Pharmaceutical Inc?
or
Market is currently closed. Voting is open during market hours.

Biomarin Pharmaceutical Inc News

Biomarin Pharmaceutical Inc Analysis

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesBuySellNeutralBuyBuy
Technical IndicatorsStrong BuyNeutralStrong SellStrong BuySell
SummaryStrong BuyNeutralSellStrong BuyNeutral

Biomarin Pharmaceutical Inc Company Profile

Biomarin Pharmaceutical Inc Company Profile

Employees
3059

BioMarin Pharmaceutical Inc. is a biotechnology company. The Company develops and commercializes pharmaceuticals for various diseases and medical conditions. As of December 31, 2016, the Company's therapy portfolio consisted of five products, and multiple clinical and pre-clinical product candidates. Its commercial products include Aldurazyme (laronidase) for Mucopolysaccharidosis I (MPS I), Firdapse (amifampridine phosphate) for Lambert Eaton Myasthenic Syndrome (LEMS), Kuvan (sapropterin dihydrochloride) for phenylketonuria (PKU), Naglazyme (galsulfase) for Mucopolysaccharidosis VI (MPS VI) and Vimizim (elosulfase alpha) for Mucopolysaccharidosis IV Type A (MPS IV A). The Company is conducting clinical trials on various product candidates for the treatment of various diseases. Its clinical product candidates include Brineura, pegvaliase, vosoritide, BMN 270 and BMN 250.

Read More
  • Give the anti-corona spray from marinomed-biotech some VC and invest in a pharma company which is heading to the moon:https://www.investing.com/equities/marinomed-biotech-agStudies are proving that the patented method of marinomed prevents infection with all Corona varietis including mutants. It also prevents other virus infections. They have many patents.  Do some good and get rich
    1
    • Biomarin are undervalued. They should be a 100$ stock
      0
      • This stock is sick.
        0
        • This stock is very resilient!
          0
          • Down graded PT
            0
            • what a sell? :O
              0
              • matter of time. 120$ fair value
                0
                • will see below 70$
                  3
                  • RDGL 0.125 By 1/16/2021 FDA will provide a final decision to grant or deny their request for breakthrough designation.
                    1
                    • KBNT and TUSK double the price very soon.. Don't miss it.. Low volume.. Fast movement.. Just give it sometime.. Good luck guys..
                      0
                      • this is going to drop to below 75 any day and any time - good buy at $65.00 for shorts
                        0
                        • wow people on August 19th must have cried alot !
                          1
                          • Cocrystal Pharma, Inc. (COCP), up 45%
                            0
                            • so we missed it..what is the point ?
                              0
                            • u r full of crab with a P!!
                              0
                          • ready to fly
                            0
                            • today will bull?
                              1
                              • Expensive even at $10. Crooks had ballooned the price to 131
                                2
                                • Take a breather.
                                  0
                                • Justin Hall Not far $40, not a bad bearish call made at $131 :).  50% down, another 20% from ATH to go.  If anyone can't wait for $10 buy, he/she can enter at $40.  Not a bad deal
                                  0
                              • FDA rejection on gene therapy
                                1
                                • Hmmm.
                                  0
                              • what happened?
                                0
                                • News bmrn might be bought out
                                  0
                                  • Any view on tomarow result ?
                                    4
                                    • Solid pipeline. Leader in gene therapy manufacturing
                                      1
                                      • $BMRN To Highlight Breadth of Innovative Development Pipeline at R&D Day on October 18th in New York STAY TUNED Big catalysts coming!!!
                                        1
                                        • $BMRN is OVERWEIGHHT with PT $117 from Morgan Stanley
                                          1
                                          • $BMRN 10 Weeks SMA is crossing over 50 Weeks SMA.. Miller time!
                                            0
                                            Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
                                            Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.